Resmetirom Patent Expiration
Resmetirom is Used for treating adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. It was first introduced by Madrigal Pharmaceuticals Inc
Resmetirom Patents
Given below is the list of patents protecting Resmetirom, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rezdiffra | US12377104 | Feb 04, 2045 | Madrigal | |
| Rezdiffra | US12667575 | Methods For Treating A Fatty Liver Disease | Feb 04, 2045 | Madrigal |
| Rezdiffra | US12661359 | Therapeutic Combinations Of Rosuvastatin And Resmetirom For The Treatment Of Liver Disorders Or Lipid Disorders | Jan 28, 2042 | Madrigal |
| Rezdiffra | US10376517 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | Sep 17, 2033 | Madrigal |
| Rezdiffra | US11564926 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | Sep 17, 2033 | Madrigal |
| Rezdiffra | US11986481 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | Sep 17, 2033 | Madrigal |
| Rezdiffra | US9266861 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | Sep 17, 2033 | Madrigal |
| Rezdiffra | US7452882 | Thyroid hormone analogs | Sep 12, 2027 | Madrigal |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Resmetirom's patents.
Latest Legal Activities on Resmetirom's Patents
Given below is the list recent legal activities going on the following patents of Resmetirom.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 27 Jan, 2026 | US9266861 |
| transaction for FDA Determination of Regulatory Review Period | 27 Jan, 2026 | US7452882 |
| transaction for FDA Determination of Regulatory Review Period | 21 Nov, 2025 | US7452882 |
| transaction for FDA Determination of Regulatory Review Period | 21 Nov, 2025 | US9266861 |
| Second letter to regulating agency to determine regulatory review period | 19 Aug, 2025 | US7452882 |
| Second letter to regulating agency to determine regulatory review period | 19 Aug, 2025 | US9266861 |
| Letter from FDA or Dept of Agriculture re PTE application | 12 Aug, 2025 | US9266861 |
| Letter from FDA or Dept of Agriculture re PTE application | 12 Aug, 2025 | US7452882 |
| Information Disclosure Statement (IDS) Filed | 12 Aug, 2025 | US7452882 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 26 Jun, 2024 | US7452882 |
Resmetirom's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Resmetirom:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
